The two companies also signed an MOU for the joint development of exosome-based diagnostic and treatment solutions.
Under the newly signed contract, Exosome Plus will exclusively supply its high-efficiency exosome isolation kit 'Exo2DTM' to Macrogen for one year.
Also, according to the contract, Macrogen may sell the isolation kits to third parties.
Macrogen will use the isolation kits for its 'exosomal RNA and DNA sequencing service' a new high added value product that Macrogen offers to the research market.
The use of the isolation kits is expected to improve production efficiency and service stability. Macrogen also plans to sell the isolation kits across its domestic and global distribution network, creating additional profits.
In addition to the supply contract, the two companies also signed an MOU for mutual collaboration.
Under the MOU, both companies agreed to work together closely for R and D and business development in the areas of exosome-based disease diagnosis and treatment.
Specifically, the MOU covers: the development of exosome-based biomarkers for early diagnosis; the development of therapeutic agents; applied uses such as drug delivery carriers, vaccines, and cosmetics; cooperative education and training to foster the manpower necessary for the development of pharmaceuticals; and the joint use of infrastructure, including equipment and facilities.
Macrogen and Exosome Plus will also be participating in the 2019 meeting of the International Society for Extracellular Vesicles to be held in Kyoto, Japan from April 25 to 28.
At the conference, the two companies will jointly present their exosome isolation and nucleic acid analysis technologies.
Starting with the ISEV meeting, Macrogen and Exosome Plus will actively engage in joint marketing for the development of domestic and overseas markets.
According to the market research organization Grand View Research, based in the USA, the global exosome market is expected to grow to approximately 2.28 bn by 2030.
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
ECO Animal Health Group receives EU approval for ECOVAXXIN trademark
China accepts GSK's Shingrix application for at-risk adults
GSK seeks US approval for RSV vaccine in at-risk adults aged 50-59